UK Markets close in 58 mins

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
6.750.00 (0.00%)
As of 10:21AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close6.75
Open6.75
Bid0.00 x 0
Ask0.00 x 0
Day's range6.75 - 6.75
52-week range5.00 - 26.69
Volume20
Avg. volume401
Market cap606.047M
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-0.65
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

    LONDON, May 18, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, on May 23-26, 2022.

  • Business Wire

    Silence Therapeutics Reports First Quarter 2022 Results

    LONDON, May 16, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today reported its financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.

  • Business Wire

    Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration

    LONDON, April 25, 2022--Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited ("Hansoh") following the achievement of an undisclosed preclinical milestone.